Hematuria differential diagnosis: Difference between revisions
Line 15: | Line 15: | ||
! colspan="3" rowspan="5" |Diseases | ! colspan="3" rowspan="5" |Diseases | ||
| colspan="9" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations''' | | colspan="9" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations''' | ||
! colspan=" | ! colspan="6" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings | ||
| colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard''' | | colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard''' | ||
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings | ! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings | ||
Line 22: | Line 22: | ||
! colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination | ! colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination | ||
|- | |- | ||
! | ! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings | ||
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging | ! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging | ||
! colspan=" | ! colspan="2" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology | ||
|- | |- | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Low back pain | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Low back pain | ||
! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever | ! colspan="1" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Nausea/Vomiting | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Nausea/ | ||
Vomiting | |||
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Urinary symptoms | ! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Urinary symptoms | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Hypertension | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Hypertension | ||
Line 40: | Line 41: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Frequency | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Frequency | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Oliguria | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Oliguria | ||
! | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Light microscopy | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Immunoflourescence pattern | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Immunoflourescence pattern | ||
|- | |- | ||
| rowspan=" | | rowspan="47" style="background: #DCDCDC; padding: 5px; text-align: center;" |Hematuria | ||
| rowspan=" | | rowspan="9" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Glomerular disease|Glomerular diseases]] | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[IgA nephropathy|IgA nephropathy (Berger nephropathy)]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[IgA nephropathy|IgA nephropathy (Berger nephropathy)]] | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 55: | Line 56: | ||
| style="background: #F5F5F5; padding: 5px;" | + | | style="background: #F5F5F5; padding: 5px;" | + | ||
| style="background: #F5F5F5; padding: 5px;" | - | | style="background: #F5F5F5; padding: 5px;" | - | ||
| | | style="background: #F5F5F5; padding: 5px;" | - | ||
| style="background: #F5F5F5; padding: 5px;" | - | | style="background: #F5F5F5; padding: 5px;" | - | ||
| style="background: #F5F5F5; padding: 5px;" | - | | style="background: #F5F5F5; padding: 5px;" | - | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* Electron microscopy shows mesangial hypercellularity and increased mesangial matrix | * Electron microscopy shows mesangial hypercellularity and increased mesangial matrix | ||
| | | style="background: #F5F5F5; padding: 5px;" | | ||
* Focal or diffuse mesangial proliferation | * Focal or diffuse mesangial proliferation | ||
* Extracellular matrix expansion | * Extracellular matrix expansion | ||
Line 81: | Line 82: | ||
* Hearing loss | * Hearing loss | ||
| | | style="background: #F5F5F5; padding: 5px;" | | ||
* [[Pyuria]] | * [[Pyuria]] | ||
* Red cell [[casts]] | * Red cell [[casts]] | ||
Line 90: | Line 91: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* High-frequency sensorineural hearing loss | * High-frequency sensorineural hearing loss | ||
| | | style="background: #F5F5F5; padding: 5px;" | - | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* Monoclonal antibodies directed against alpha-3 (IV), alpha-4 (IV), and alpha-5 (IV) chains of type IV collagen | * Monoclonal antibodies directed against alpha-3 (IV), alpha-4 (IV), and alpha-5 (IV) chains of type IV collagen | ||
Line 112: | Line 113: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* Urine samples for protein and blood | * Urine samples for protein and blood | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Renal Biopsy | Renal Biopsy | ||
Line 124: | Line 124: | ||
* Endothelial and mesangial cells and migrant inflammatory cells | * Endothelial and mesangial cells and migrant inflammatory cells | ||
* Hyaline droplets | * Hyaline droplets | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* Immunoglobulin G and C3 in a diffuse granular pattern | * Immunoglobulin G and C3 in a diffuse granular pattern | ||
Line 151: | Line 150: | ||
* Hepatitis B or C infection | * Hepatitis B or C infection | ||
* Antineutrophil cytoplasmic antibody titers, serum protein electrophoresis | * Antineutrophil cytoplasmic antibody titers, serum protein electrophoresis | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* Shrunken kidneys | * Shrunken kidneys | ||
Line 158: | Line 156: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* Segmental solidification in the perihilar region and peripheral areas, specially the tubular pole | * Segmental solidification in the perihilar region and peripheral areas, specially the tubular pole | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* Coarsely granular deposits of IgM and C3 | * Coarsely granular deposits of IgM and C3 | ||
Line 186: | Line 183: | ||
* Eleated LDH and CPK | * Eleated LDH and CPK | ||
* Proteinuria | * Proteinuria | ||
| style="background: #F5F5F5; padding: 5px;" | - | | style="background: #F5F5F5; padding: 5px;" | - | ||
| style="background: #F5F5F5; padding: 5px;" | - | | style="background: #F5F5F5; padding: 5px;" | - | ||
| style="background: #F5F5F5; padding: 5px;" | - | | style="background: #F5F5F5; padding: 5px;" | - | ||
| style="background: #F5F5F5; padding: 5px;" |Diffuse, proliferative, necrotizing glomerulonephritis with crescent formation | | style="background: #F5F5F5; padding: 5px;" |Diffuse, proliferative, necrotizing glomerulonephritis with crescent formation | ||
| style="background: #F5F5F5; padding: 5px;" | - | | style="background: #F5F5F5; padding: 5px;" | - | ||
| style="background: #F5F5F5; padding: 5px;" |Biospy | | style="background: #F5F5F5; padding: 5px;" |Biospy | ||
Line 214: | Line 209: | ||
* Cellular casts | * Cellular casts | ||
* Low iron | * Low iron | ||
| style="background: #F5F5F5; padding: 5px;" | - | | style="background: #F5F5F5; padding: 5px;" | - | ||
| style="background: #F5F5F5; padding: 5px;" | - | | style="background: #F5F5F5; padding: 5px;" | - | ||
| style="background: #F5F5F5; padding: 5px;" | - | | style="background: #F5F5F5; padding: 5px;" | - | ||
| style="background: #F5F5F5; padding: 5px;" | - | | style="background: #F5F5F5; padding: 5px;" | - | ||
| style="background: #F5F5F5; padding: 5px;" | - | | style="background: #F5F5F5; padding: 5px;" | - | ||
| style="background: #F5F5F5; padding: 5px;" |Biopsy | | style="background: #F5F5F5; padding: 5px;" |Biopsy | ||
Line 225: | Line 218: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Thin basement membrane disease]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Thin basement membrane disease]] | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 245: | Line 236: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Fabry's disease|Fabry disease]] | | rowspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Fabry's disease|Fabry disease]] | ||
| style="background: #F5F5F5; padding: 5px;" | - | | style="background: #F5F5F5; padding: 5px;" | - | ||
| style="background: #F5F5F5; padding: 5px;" | - | | style="background: #F5F5F5; padding: 5px;" | - | ||
Line 258: | Line 249: | ||
* Hematuria | * Hematuria | ||
* Proteinuria | * Proteinuria | ||
| style="background: #F5F5F5; padding: 5px;" | - | | style="background: #F5F5F5; padding: 5px;" | - | ||
| style="background: #F5F5F5; padding: 5px;" | - | | style="background: #F5F5F5; padding: 5px;" | - | ||
| style="background: #F5F5F5; padding: 5px;" | - | | style="background: #F5F5F5; padding: 5px;" | - | ||
| style="background: #F5F5F5; padding: 5px;" |Non-specific+/- nephrotic picture | | style="background: #F5F5F5; padding: 5px;" |Non-specific+/- nephrotic picture | ||
| style="background: #F5F5F5; padding: 5px;" | - | | style="background: #F5F5F5; padding: 5px;" | - | ||
| style="background: #F5F5F5; padding: 5px;" | - | | style="background: #F5F5F5; padding: 5px;" | - | ||
| style="background: #F5F5F5; padding: 5px;" | - | | style="background: #F5F5F5; padding: 5px;" | - | ||
|- | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |- | ||
| rowspan="5" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Tubulointerstitial diseases of the kidney|Tubulointerstitial diseases]] | | rowspan="5" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Tubulointerstitial diseases of the kidney|Tubulointerstitial diseases]] | ||
Line 283: | Line 290: | ||
* [[Pyuria]] | * [[Pyuria]] | ||
* [[Microscopic hematuria]] | * [[Microscopic hematuria]] | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 290: | Line 296: | ||
* Non-enhanced lesions surrounded by rings of excreted contrast material | * Non-enhanced lesions surrounded by rings of excreted contrast material | ||
* Hyperattenuated [[medullary]][[Calcification|calcifications]] | * Hyperattenuated [[medullary]][[Calcification|calcifications]] | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 301: | Line 306: | ||
| style="background: #F5F5F5; padding: 5px;" | + | | style="background: #F5F5F5; padding: 5px;" | + | ||
| style="background: #F5F5F5; padding: 5px;" | + | | style="background: #F5F5F5; padding: 5px;" | + | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 319: | Line 322: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Analgesic]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Analgesic]] | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 340: | Line 341: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Nephrolithiasis]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Nephrolithiasis]] | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | + | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 361: | Line 360: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Reflux nephropathy|Reflux nephropathy (hydronephrosis)]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Reflux nephropathy|Reflux nephropathy (hydronephrosis)]] | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | + | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 381: | Line 378: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| rowspan=" | | rowspan="5" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Malignancy]] | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Renal cell carcinoma|Renal cell carcinoma (RCC)]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Renal cell carcinoma|Renal cell carcinoma (RCC)]] | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" |– | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 404: | Line 399: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Nephroblastoma]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Nephroblastoma]] | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 425: | Line 418: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Transitional cell carcinoma|Transitional cell carcinoma (TCC)]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Transitional cell carcinoma|Transitional cell carcinoma (TCC)]] | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 445: | Line 436: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Prostate cancer]] | | rowspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Prostate cancer]] | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 465: | Line 454: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Familial|Familial diseases]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Familial|Familial diseases]] | ||
Line 480: | Line 487: | ||
* Palpable [[abdominal]] [[mass]] in the [[lumbar]] quadrant | * Palpable [[abdominal]] [[mass]] in the [[lumbar]] quadrant | ||
* [[Palpable]] [[nodular]] [[hepatomegaly]] | * [[Palpable]] [[nodular]] [[hepatomegaly]] | ||
| | | style="background: #F5F5F5; padding: 5px;" | | ||
* [[Hypocitraturia]] in 65% on patients | * [[Hypocitraturia]] in 65% on patients | ||
* [[Hyperuricemia]] in 20% of patients | * [[Hyperuricemia]] in 20% of patients | ||
Line 498: | Line 505: | ||
* Non-canonical [[splice]] site alterations | * Non-canonical [[splice]] site alterations | ||
* Combined [[missense]] changes | * Combined [[missense]] changes | ||
| | | style="background: #F5F5F5; padding: 5px;" | | ||
* Interstitial fibrosis | * Interstitial fibrosis | ||
* Tubular atrophy | * Tubular atrophy | ||
Line 522: | Line 529: | ||
* Abdominal pain | * Abdominal pain | ||
* Acute in onset | * Acute in onset | ||
| | | rowspan="2" style="background: #F5F5F5; padding: 5px;" | | ||
* Elevation in serum lactate dehydrogenase | * Elevation in serum lactate dehydrogenase | ||
* Cholesterol levels for hypercholesterolemia | * Cholesterol levels for hypercholesterolemia | ||
Line 532: | Line 539: | ||
| rowspan="2" style="background: #F5F5F5; padding: 5px;" | | | rowspan="2" style="background: #F5F5F5; padding: 5px;" | | ||
* '''Renal venography:''' Gold standard | * '''Renal venography:''' Gold standard | ||
| | | rowspan="2" style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 555: | Line 562: | ||
* [[Unintentional weight loss]] | * [[Unintentional weight loss]] | ||
* [[Muscle aches]] | * [[Muscle aches]] | ||
| | | style="background: #F5F5F5; padding: 5px;" | | ||
* [[Complete blood count|CBC]] may show: | * [[Complete blood count|CBC]] may show: | ||
** Leukocytosis | ** Leukocytosis | ||
Line 564: | Line 571: | ||
* [[Erythrocyte sedimentation rate|ESR]] and [[C-reactive protein]] | * [[Erythrocyte sedimentation rate|ESR]] and [[C-reactive protein]] | ||
* Hepatitis B surface antigen and hepatitic C serologies | * Hepatitis B surface antigen and hepatitic C serologies | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 583: | Line 589: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 603: | Line 608: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 613: | Line 617: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| rowspan=" | | rowspan="5" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Urinary system|Lower urinary tract diseases]] | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Benign prostatic hyperplasia]] | | rowspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Benign prostatic hyperplasia]] | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 624: | Line 628: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 633: | Line 636: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Urolithiasis]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Urolithiasis]] | ||
Line 644: | Line 665: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 664: | Line 684: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 684: | Line 703: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 705: | Line 723: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 725: | Line 742: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 745: | Line 761: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 765: | Line 780: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 785: | Line 799: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 795: | Line 808: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| rowspan=" | | rowspan="9" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Infectious disease|Infectious diseases]] | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Pyelonephritis]] | | rowspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Pyelonephritis]] | ||
| style="background: #F5F5F5; padding: 5px;" | + | | style="background: #F5F5F5; padding: 5px;" | + | ||
| style="background: #F5F5F5; padding: 5px;" | + | | style="background: #F5F5F5; padding: 5px;" | + | ||
Line 808: | Line 821: | ||
* [[Delirium]] | * [[Delirium]] | ||
* [[Headache]] | * [[Headache]] | ||
| | | style="background: #F5F5F5; padding: 5px;" | | ||
* Positive [[leukocyte esterase]] test and [[nitrite test]]. | * Positive [[leukocyte esterase]] test and [[nitrite test]]. | ||
* Blood/urine cultures | * Blood/urine cultures | ||
Line 820: | Line 833: | ||
Contrast nephrograms | Contrast nephrograms | ||
* Focal areas of striated or wedge-shaped [[hypoperfusion]] | * Focal areas of striated or wedge-shaped [[hypoperfusion]] | ||
| | | style="background: #F5F5F5; padding: 5px;" | | ||
*[[Neutrophils]] | *[[Neutrophils]] | ||
*Interstitial fibrosis | *Interstitial fibrosis | ||
Line 827: | Line 840: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Cystitis]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Cystitis]] | ||
Line 840: | Line 871: | ||
* [[Dyspareunia]] | * [[Dyspareunia]] | ||
* Supra pubic tenderness | * Supra pubic tenderness | ||
| | | style="background: #F5F5F5; padding: 5px;" | | ||
* [[Pyuria]]: > 5-10 WBC/hpf or 27 [[WBC]]/microliter | * [[Pyuria]]: > 5-10 WBC/hpf or 27 [[WBC]]/microliter | ||
* Positive [[leukocyte esterase]] test and [[nitrite test]]. | * Positive [[leukocyte esterase]] test and [[nitrite test]]. | ||
Line 853: | Line 884: | ||
* [[Hydronephrosis]] | * [[Hydronephrosis]] | ||
* [[Calcification]] | * [[Calcification]] | ||
| | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 869: | Line 900: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* Body aches | * Body aches | ||
| | | style="background: #F5F5F5; padding: 5px;" | | ||
* Increased [[leukocytes]] (>10 per high power field) on CBC | * Increased [[leukocytes]] (>10 per high power field) on CBC | ||
* Bacteria seen on [[urine culture]] | * Bacteria seen on [[urine culture]] | ||
Line 880: | Line 911: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* Hyperintense lesions on MRI | * Hyperintense lesions on MRI | ||
| | | style="background: #F5F5F5; padding: 5px;" | | ||
* [[Neutrophils]] | * [[Neutrophils]] | ||
* Between the epithelial cells or inside the stroma. | * Between the epithelial cells or inside the stroma. | ||
Line 898: | Line 929: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* Urethral discharge | * Urethral discharge | ||
| | | style="background: #F5F5F5; padding: 5px;" | | ||
* Mucoid, [[mucopurulent]], or [[purulent]] [[discharge]] | * Mucoid, [[mucopurulent]], or [[purulent]] [[discharge]] | ||
* [[Gram staining|Gram stain]] of urethral secretions demonstrating ≥2 [[WBC]] per field | * [[Gram staining|Gram stain]] of urethral secretions demonstrating ≥2 [[WBC]] per field | ||
Line 908: | Line 939: | ||
* Periureteric or perinephric fat stranding. | * Periureteric or perinephric fat stranding. | ||
| style="background: #F5F5F5; padding: 5px;" | - | | style="background: #F5F5F5; padding: 5px;" | - | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 921: | Line 951: | ||
| style="background: #F5F5F5; padding: 5px;" | - | | style="background: #F5F5F5; padding: 5px;" | - | ||
| style="background: #F5F5F5; padding: 5px;" | - | | style="background: #F5F5F5; padding: 5px;" | - | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 936: | Line 964: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Cytomegalovirus]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Cytomegalovirus]] | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 957: | Line 983: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Infectious mononucleosis]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Infectious mononucleosis]] | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 978: | Line 1,002: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Condylomata acuminata]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Condylomata acuminata]] | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 1,000: | Line 1,022: | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Urogenital|Urogenital trauma]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Urogenital|Urogenital trauma]] | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Inserted [[bladder]] or [[Ureteral disease|ureteral catheters]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Inserted [[bladder]] or [[Ureteral disease|ureteral catheters]] | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 1,020: | Line 1,040: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Drugs]] | | rowspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Drugs]] | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Anticoagulants]] | | rowspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Anticoagulants]] | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 1,042: | Line 1,060: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| rowspan=" | | | ||
| rowspan=" | | | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
| rowspan="15" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Dark urine]] | |||
| rowspan="7" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Hemoglobinuria]] | |||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Autoimmune hemolytic anemia]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Autoimmune hemolytic anemia]] | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 1,066: | Line 1,100: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Microangiopathic hemolytic anemia]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Microangiopathic hemolytic anemia]] | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 1,087: | Line 1,119: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Thrombotic thrombocytopenic purpura]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Thrombotic thrombocytopenic purpura]] | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 1,108: | Line 1,138: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Paroxysmal nocturnal hemoglobinuria]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Paroxysmal nocturnal hemoglobinuria]] | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 1,129: | Line 1,157: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Paroxysmal cold hemoglobinuria]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Paroxysmal cold hemoglobinuria]] | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 1,149: | Line 1,175: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Malaria|Falciparum malaria]] | | rowspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Malaria|Falciparum malaria]] | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 1,169: | Line 1,193: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |- | ||
| rowspan="8" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Myoglobinuria]] | | rowspan="8" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Myoglobinuria]] | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Crush injury]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Crush injury]] | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 1,193: | Line 1,233: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Physical exercise|Vigorous muscle exercise]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Physical exercise|Vigorous muscle exercise]] | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 1,214: | Line 1,252: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Hyperthermia|Hyperthermia (Heat stroke)]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Hyperthermia|Hyperthermia (Heat stroke)]] | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 1,235: | Line 1,271: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Electric shock]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Electric shock]] | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 1,256: | Line 1,290: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Prolonged [[seizure]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Prolonged [[seizure]] | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 1,277: | Line 1,309: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Polymyositis]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Polymyositis]] | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 1,298: | Line 1,328: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Trichinosis]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Trichinosis]] | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 1,319: | Line 1,347: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Haff disease]] | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Haff disease]] | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | |
Revision as of 15:18, 23 July 2018
Hematuria Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Hematuria differential diagnosis On the Web |
American Roentgen Ray Society Images of Hematuria differential diagnosis |
Risk calculators and risk factors for Hematuria differential diagnosis |
Steven C. Campbell, M.D., Ph.D. Associate Editor(s)-in-Chief: Venkata Sivakrishna Kumar Pulivarthi M.B.B.S [1] Omer Kamal, M.D.[2
Overview
Gross hematuria(GH) must be distinguished from pigmenturia, which may be due to endogenous sources (e.g., bilirubin, myoglobin,and porphyrins), foods ingested (e.g., beets and rhubarb), drugs (e.g., phenazopyridine), and simple dehydration. This distinction can be made easily by urinalysis with microscopy. Notably, myoglobinuria and other factors can cause false-positive chemical tests for hemoglobin, so urine microscopy is required to confirm the diagnosis of hematuria. GH also must be distinguished from vaginal bleeding in women, which usually can be achieved by obtaining a careful menstrual history, collecting the specimen when the patient is not having menstrual or gynecologic bleeding, or, if necessary, obtaining a catheterized specimen. GH may also be detected by the presence of blood spotting on the undergarments of incontinent patients. After ruling out vaginal bleeding and mimics of hematuria, a urologic source must be suspected.
Differential Diagnosis
Hematuria should be differentiated from other disease which mimic hematuria especially hemoglobinuria and myoglobinuria which are dipstick positive but negative for microscopy.
Hematuria differential diagnosis
Differentiating the diseases that can cause hematuria:
Diseases | Clinical manifestations | Para-clinical findings | Gold standard | Additional findings | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Symptoms | Physical examination | ||||||||||||||||||
Lab Findings | Imaging | Histopathology | |||||||||||||||||
Low back pain | Fever | Nausea/
Vomiting |
Urinary symptoms | Hypertension | Pitting edema | Other | Ultrasonography | CT scan | Other | ||||||||||
Dysuria | Frequency | Oliguria | Light microscopy | Immunoflourescence pattern | |||||||||||||||
Hematuria | Glomerular diseases | IgA nephropathy (Berger nephropathy) | + | - | - | - | + | + | + | - | - | - | - |
|
|
|
Biopsy | - | |
Hereditary nephritis (Alport syndrome) | - | - | - | - | - | - | + | - |
|
|
- |
|
- |
|
|
- | |||
Poststreptococcal glomerulonephritis | +/- | + | - | - | + | + | + | + |
|
|
Renal Biopsy
|
- | - |
|
|
Biopsy | - | ||
Focal segmental glomerular sclerosis | - | - | - | - | - | - | + | + |
|
|
|
- | - |
|
|
Biopsy | - | ||
Rapidly progressive glomerulonephritis | + | + | + | - | - | - | + | - |
|
|
- | - | - | Diffuse, proliferative, necrotizing glomerulonephritis with crescent formation | - | Biospy | 80% of patients have ANCA-positive microscopic polyangiitis | ||
Lupus nephritis | - | + | - | - | - | - | + | + |
|
|
- | - | - | - | - | Biopsy | - | ||
Thin basement membrane disease | |||||||||||||||||||
Fabry disease | - | - | - | - | - | - | + | + | - |
|
- | - | - | Non-specific+/- nephrotic picture | - | - | - | ||
Tubulointerstitial diseases | Renal papillary necrosis | Flank pain | + | – | + | + | ± | Hypotension | ± |
|
|||||||||
Acute interstitial nephritis | + | + | + | ||||||||||||||||
Analgesic | |||||||||||||||||||
Nephrolithiasis | + | ||||||||||||||||||
Reflux nephropathy (hydronephrosis) | + | ||||||||||||||||||
Malignancy | Renal cell carcinoma (RCC) | – | |||||||||||||||||
Nephroblastoma | |||||||||||||||||||
Transitional cell carcinoma (TCC) | |||||||||||||||||||
Prostate cancer | |||||||||||||||||||
Familial diseases | Polycystic kidney disease | + | - | - | - | - | - | + | + |
|
|
|
Genetic testing demonstrates: |
|
|
Ultrasound | |||
Vascular diseases | Renal vein thrombosis | + | + | + | - | - | - | - | - |
|
|
|
|
||||||
Polyarteritis nodosa | - | -/+ | - | - | - | + | + | - |
|
||||||||||
Wegner's granulomatosis polyangiitis | |||||||||||||||||||
Henoch-Schönlein purpura | |||||||||||||||||||
Lower urinary tract diseases | Benign prostatic hyperplasia | ||||||||||||||||||
Urolithiasis | |||||||||||||||||||
Interstitial cystitis | |||||||||||||||||||
Radiogenic cystitis | |||||||||||||||||||
Systemic diseases | Coagulopathy (hemophilia) | ||||||||||||||||||
Sickle cell anemia | |||||||||||||||||||
Abdominal aortic aneurysm | |||||||||||||||||||
Lymphomas | |||||||||||||||||||
Multiple myeloma | |||||||||||||||||||
Infectious diseases | Pyelonephritis | + | + | + | + | + | + | - | - |
|
|
Contrast nephrograms
|
|
- | |||||
Cystitis | - | - | - | + | + | + | - | - |
|
|
|
MRI
|
|||||||
Prostatitis | - | + | - | + | + | + | - | - |
|
|
|
|
|
|
|||||
Urethritis | -/- | + | - | + | + | + | - | - |
|
|
- |
|
- | ||||||
Epididymitis | -/+ | + | + | - | - | - | |||||||||||||
Cytomegalovirus | |||||||||||||||||||
Infectious mononucleosis | |||||||||||||||||||
Condylomata acuminata | |||||||||||||||||||
Urogenital trauma | Inserted bladder or ureteral catheters | ||||||||||||||||||
Drugs | Anticoagulants | ||||||||||||||||||
Dark urine | Hemoglobinuria | Autoimmune hemolytic anemia | |||||||||||||||||
Microangiopathic hemolytic anemia | |||||||||||||||||||
Thrombotic thrombocytopenic purpura | |||||||||||||||||||
Paroxysmal nocturnal hemoglobinuria | |||||||||||||||||||
Paroxysmal cold hemoglobinuria | |||||||||||||||||||
Falciparum malaria | |||||||||||||||||||
Myoglobinuria | Crush injury | ||||||||||||||||||
Vigorous muscle exercise | |||||||||||||||||||
Hyperthermia (Heat stroke) | |||||||||||||||||||
Electric shock | |||||||||||||||||||
Prolonged seizure | |||||||||||||||||||
Polymyositis | |||||||||||||||||||
Trichinosis | |||||||||||||||||||
Haff disease |